Your browser doesn't support javascript.
loading
Challenges in neoantigen-directed therapeutics.
Lybaert, Lien; Lefever, Steve; Fant, Bruno; Smits, Evelien; De Geest, Bruno; Breckpot, Karine; Dirix, Luc; Feldman, Steven A; van Criekinge, Wim; Thielemans, Kris; van der Burg, Sjoerd H; Ott, Patrick A; Bogaert, Cedric.
Afiliação
  • Lybaert L; myNEO NV, 9000 Ghent, Belgium.
  • Lefever S; myNEO NV, 9000 Ghent, Belgium.
  • Fant B; myNEO NV, 9000 Ghent, Belgium.
  • Smits E; Center for Oncological Research, University of Antwerp, 2610 Wilrijk, Belgium.
  • De Geest B; Department of Pharmaceutics, Ghent University, 9000 Ghent, Belgium.
  • Breckpot K; Laboratory of Molecular and Cellular Therapy, Department of Biomedical Sciences, Vrije Universiteit Brussel, Brussels, Belgium.
  • Dirix L; Translational Cancer Research Unit, Center for Oncological Research, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
  • Feldman SA; Center for Cancer Cell Therapy, Stanford University School of Medicine, Stanford, CA, USA.
  • van Criekinge W; Department of Data Analysis and Mathematical Modelling, Ghent University, Ghent, Belgium.
  • Thielemans K; Laboratory of Molecular and Cellular Therapy, Department of Biomedical Sciences, Vrije Universiteit Brussel, Brussels, Belgium.
  • van der Burg SH; Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, the Netherlands.
  • Ott PA; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
  • Bogaert C; myNEO NV, 9000 Ghent, Belgium. Electronic address: cedric@myneo.me.
Cancer Cell ; 41(1): 15-40, 2023 01 09.
Article em En | MEDLINE | ID: mdl-36368320
ABSTRACT
A fundamental prerequisite for the efficacy of cancer immunotherapy is the presence of functional, antigen-specific T cells within the tumor. Neoantigen-directed therapy is a promising strategy that aims at targeting the host's immune response against tumor-specific antigens, thereby eradicating cancer cells. Initial forays have been made in clinical environments utilizing vaccines and adoptive cell therapy; however, many challenges lie ahead. We provide an in-depth overview of the current state of the field with an emphasis on in silico neoantigen discovery and the clinical aspects that need to be addressed to unlock the full potential of this therapy.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas Anticâncer / Neoplasias Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas Anticâncer / Neoplasias Idioma: En Ano de publicação: 2023 Tipo de documento: Article